Omega Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 20.13 million compared to USD 25.28 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 0.5 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.07 USD | -7.59% | -14.81% | -31.23% |
06-24 | Omega Therapeutics, Inc. Appoints Richard N. Kender to Board of Directors | CI |
06-18 | Raymond James Initiates Omega Therapeutics at Outperform Rating With $12 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.23% | 114M | |
+19.41% | 45.51B | |
+38.65% | 38.13B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- OMGA Stock
- News Omega Therapeutics, Inc.
- Omega Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024